Report Highlights

U.S. Protein Therapeutics: Market Overview

The U.S. protein therapeutics market is the largest in the world, accounting for roughly 45% of global biologic drug revenues, driven by a combination of high per-capita healthcare spending, a broad FDA-approved product portfolio, and a reimbursement infrastructure that historically favored branded biologics. The market's current structure was fundamentally shaped by the Biologics Price Competition and Innovation Act of 2009 (BPCIA), which established the 12-year exclusivity window for reference products and created the abbreviated regulatory pathway — Section 351(k) of the Public Health Service Act — for biosimilar approvals. Private sector innovation has been the primary engine of pipeline development, while federal programmes including Medicare Part B and Part D serve as the dominant reimbursement channels.

Government has played a structuring rather than a directing role, with the Centers for Medicare and Medicaid Services (CMS) determining reimbursement rates that effectively set commercial pricing ceilings. The market is segmented by product class — with monoclonal antibodies representing the largest share at approximately 52% of revenues — followed by insulin and insulin analogues, clotting factors, and cytokines. Oncology, immunology, and diabetes are the three highest-revenue therapeutic areas. The transition from a purely branded market to one with meaningful biosimilar competition is underway but slower than comparable European markets due to structural PBM and rebate dynamics that insulate originator products.

Policy-Driven Growth in U.S. Protein Therapeutics

Three policy mechanisms are directly driving demand expansion in this market. First, the Inflation Reduction Act of 2022 (IRA, Public Law 117-169) authorizes CMS to negotiate prices on a defined list of high-expenditure drugs beginning with ten products in 2026. Because the IRA exempts biologics under their exclusivity period and applies negotiation timelines that favor complex molecules, manufacturers are accelerating protein therapeutic launches. The IRA also caps Medicare Part D out-of-pocket costs at $2,000 annually starting 2025, expanding patient access and effective demand volume for high-cost biologics including adalimumab, etanercept, and pembrolizumab.

Second, the FDA's Biosimilar Action Plan, updated through CDER's Biosimilar Program goals under PDUFA VII commitments, targets a 90-day standard review completion rate for biosimilar applications — compressing time-to-market and increasing competitive supply. Third, the 340B Drug Pricing Program, administered by the Health Resources and Services Administration (HRSA), obliges manufacturers to provide discounted biologics to qualifying covered entities including disproportionate share hospitals, generating subsidized demand worth an estimated $44 billion annually across eligible drug classes. Each of these mechanisms directly translates into expanded unit volume or compressed pricing that stimulates broader market uptake of protein therapeutics.

Regulatory Barriers and Compliance Costs

The primary regulatory barrier is the complexity and cost of the 351(k) biosimilar approval pathway administered by FDA's Center for Drug Evaluation and Research (CDER). Achieving biosimilarity designation requires extensive analytical, preclinical, and clinical data packages that typically cost $100–250 million per programme and take eight to twelve years to complete. The interchangeability designation — required for automatic pharmacy-level substitution in most U.S. states — demands additional switching studies, adding eighteen to thirty-six months to development timelines. The FDA's Purple Book database lists current biosimilar and interchangeability statuses, but the pathway remains substantially more burdensome than equivalent EMA procedures, suppressing the number of competitive entrants per reference product.

Additional compliance costs arise from the Drug Supply Chain Security Act (DSCSA), fully enforced from November 2024, which mandates electronic, interoperable unit-level traceability for all prescription drug products including biologics. Manufacturers must integrate serialization and verification systems meeting FDA's electronic product identifier requirements, with enforcement by FDA's Office of Pharmaceutical Quality. Non-compliance risks product holds and import alerts. Separately, the 340B programme's audit and recertification requirements, overseen by HRSA's Office of Pharmacy Affairs, generate recurring administrative costs estimated at $2–5 million annually per large manufacturer, particularly as HRSA tightens contract pharmacy dispute resolution processes under its 2023 advisory guidance.

Policy-Created Opportunities in U.S. Protein Therapeutics

The most significant policy-created opportunity is the IRA's restructuring of Medicare Part D, which takes full effect in 2025–2026. The new $2,000 annual out-of-pocket cap removes the catastrophic coverage gap that previously deterred patient adherence to high-cost biologics. For manufacturers of approved monoclonal antibodies in oncology and immunology — particularly those priced above $50,000 annually — this structural change in patient cost-sharing directly increases persistence rates and total prescription volume without requiring price reductions. CMS projects that approximately 1.3 million Medicare beneficiaries will gain meaningful new access to biologics they previously underutilized due to cost barriers.

A second opportunity is created by the National Institutes of Health's National Cancer Institute (NCI) and BARDA co-funding mechanisms for next-generation protein therapeutics including bispecific antibodies and antibody-drug conjugates. BARDA's medical countermeasure procurement authority under Project BioShield allocates dedicated funding for protein-based biologics targeting pandemic and biodefence applications, with $2.4 billion available under the current FY2024–2025 cycle. Additionally, CMS's Center for Medicare and Medicaid Innovation (CMMI) is piloting outcomes-based contracting models for high-cost biologics in rheumatology and oncology — creating a policy-sanctioned framework for value-based agreements that reduce payer risk and accelerate formulary access for newly approved protein therapeutics entering the market from 2025 onward.

Market at a Glance

Leading Market Participants

• Amgen
• AbbVie
• Johnson & Johnson (Janssen Biotech)
• Genentech (Roche)
• Pfizer
• Bristol-Myers Squibb
• Eli Lilly
• Merck & Co.
• Novo Nordisk
• Regeneron Pharmaceuticals

Regulatory and Policy Environment

The foundational legislation governing protein therapeutics in the U.S. is the Public Health Service Act (PHS Act), Section 351, as amended by the Biologics Price Competition and Innovation Act of 2009. CDER — and for certain vaccine-adjacent biologics, the Center for Biologics Evaluation and Research (CBER) — administers Biologics License Applications (BLAs) under this framework. The Prescription Drug User Fee Act VII (PDUFA VII), effective through FY2027, sets binding performance goals for BLA review timelines: 90% of standard BLAs reviewed within twelve months and priority BLAs within six months. Upcoming regulatory changes include FDA's anticipated final guidance on interchangeable biosimilar labelling, expected in 2025, and expanded use of real-world evidence in biosimilar approval packages, signalled in FDA's 2023 draft guidance on RWE for biological products. Compared to regional peers, the U.S. framework is more exclusivity-protective than the EU but more transparent on approval criteria than Japan's PMDA biosimilar pathway.

The IRA introduces a transformative regulatory-pricing overlay: beginning in 2026, CMS's new Drug Negotiation Programme — administered jointly by CMS's Center for Medicare and the Office of the Secretary of HHS — will publish Maximum Fair Prices for the first ten negotiated drugs, with protein therapeutics expected to appear on subsequent negotiation lists by 2027–2028. Manufacturers must comply with price publication requirements or face an excise tax escalating from 65% to 95% of gross sales. The 340B programme remains under active litigation, with the Supreme Court's 2022 ruling in American Hospital Association v. Becerrra constraining CMS's reimbursement cut authority, while HRSA's 2023 proposed rule on duplicate discounts is expected to be finalized in 2025, adding new compliance obligations for manufacturers operating in both 340B and Medicaid channels simultaneously.

Long-Term Policy Outlook for U.S. Protein Therapeutics

By 2032, the IRA's drug negotiation programme will have expanded to cover an estimated 60 or more products across Medicare Part B and Part D. Protein therapeutics — particularly monoclonal antibodies with annual revenues exceeding $500 million — will dominate the negotiation list, creating a ceiling-price environment that compresses net revenue per unit for originator manufacturers. This will accelerate the shift in R&D investment toward first-in-class mechanisms and rare disease indications, where orphan drug exclusivity under the Orphan Drug Act (21 U.S.C. §360bb) and shorter clinical development timelines provide protected revenue windows. FDA's Centre for Excellence in Regulatory Science and Innovation (CERSI) partnerships are expected to produce updated manufacturing flexibility guidance by 2026 that enables continuous bioprocessing — reducing cost of goods for protein therapeutics and improving biosimilar economics.

Congress is expected to revisit BPCIA exclusivity provisions before 2030, with legislative proposals to shorten the 12-year exclusivity period to seven years — aligning with EU standards — gaining traction from the Congressional Budget Office's analyses showing $6 billion in potential Medicare savings. If enacted, this change would fundamentally reshape the competitive timeline for biosimilar entry and force originator manufacturers to accelerate indication expansion strategies to maximize revenue within shorter protected periods. Concurrently, the FDA's evolving framework for AI-assisted drug development review, piloted through CDER's Digital Health Center of Excellence, is projected to reduce BLA review timelines by 20–30% by 2029, opening faster market access windows for protein therapeutics and compressing the competitive response time available to incumbents.